Recent Statistics and Updates on Ozempic Gastroparesis Product Liability Lawsuits

Ozempic™, the popular brand name for Semaglutide, has been at the center of product liability lawsuits due to its alleged link to gastroparesis and other gastrointestinal conditions. As a prescription drug approved for the treatment of type-2 diabetes and increasingly used for weight management, the potential side effects of Ozempic have raised concerns and led to legal action.

Alarming Research

Recent statistics and updates regarding these product liability lawsuits provide valuable insights into the ongoing legal landscape related to Ozempic and its potential impact on individuals who have suffered adverse effects after taking the drug.

Researchers studying results from almost 300,000 patients found that people taking GLP-1 drugs were 66% more likely to be diagnosed with gastroparesis than those who were not. Among patients taking the drugs, 0.53% were diagnosed with gastroparesis — about 750 out of nearly 150,000 patients.

Another recent study links Peptide-1 Receptor Agonist Use with an increased risk of gallbladder and biliary diseases.

“Patients need to be informed about these side effects before treatment is started. There is a lot of excitement and demand for these medications, but side effects are critical points for discussion,” Prateek Sharma, MD, Professor of Medicine, Department of Medical Oncology, University of Kansas School of Medicine.

According to recent data, a significant number of individuals have filed lawsuits against the manufacturers of Ozempic, citing the development of gastroparesis and other gastrointestinal conditions as a result of using the drug. These lawsuits allege that the manufacturers failed to adequately warn patients and healthcare providers about the potential risks associated with Ozempic use, including the increased likelihood of developing serious gastrointestinal issues.

Ozempic Class-Action Lawsuit

Accordingly, in February 2024, The U.S. Judicial Panel on Multidistrict Litigation ordered that all current Ozempic lawsuits in federal court be centralized in the Eastern District of Pennsylvania. MDL 3094 In Re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAS) Products Liability Litigation has 346 litigants as of August 2023, an increase of 235 active cases over the past month, which is an over 200% jump in a single month.

These lawsuits highlight the potential connection between Ozempic use and the development of gastroparesis, a condition characterized by delayed emptying of the stomach, leading to symptoms such as nausea, vomiting and abdominal discomfort. These findings have bolstered the claims of individuals who have experienced these symptoms after taking Ozempic, further fueling the momentum of product liability lawsuits against the drug’s manufacturers.

Atlanta Defective Products Lawsuits

Anyone who has experienced adverse effects, including gastroparesis, after taking Ozempic should consult with a healthcare professional and explore their legal options with an Atlanta Defective Product Attorney from Moriarty Injury Lawyer. Seeking timely medical attention and legal guidance is crucial for individuals who believe they have been harmed by the use of Ozempic and are considering pursuing a product liability lawsuit.

Contact us today in Atlanta to schedule a consultation and discuss your options.